Results 241 to 250 of about 354,830 (305)

Bret/BRAT

open access: yes
Critical Quarterly, EarlyView.
Nicholas Smart
wiley   +1 more source

Prodrug Strategy Extends the Use of Anti-HIV Sulfanylbenzamides for Application In Vivo. [PDF]

open access: yesACS Pharmacol Transl Sci
Robello M   +5 more
europepmc   +1 more source

Novel Clinical and Histological Insights into Cutaneous Kikuchi‐Fujimoto Disease and Kikuchi Disease‐Like Inflammatory Pattern (KLIP)

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Magí Brufau‐Cochs   +7 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Bioinformatics-assisted anti-HIV therapy

Nature Reviews Microbiology, 2006
Highly active antiretroviral therapy (HAART), in which three or more drugs are given in combination, has substantially improved the clinical management of HIV-1 infection. Still, the emergence of drug-resistant variants eventually leads to therapy failure in most patients.
Thomas Lengauer, Tobias Sing
exaly   +4 more sources

Anti-HIV ribozymes

Molecular Biotechnology, 1997
HIV is an RNA virus that replicates intracellularly through various RNA intermediates. Several of these can be targeted by ribozymes (catalytic RNA molecules), and a number of investigators, including this group, have demonstrated the ability of ribozymes to suppress HIV replication in this way.
L Q, Sun   +3 more
openaire   +2 more sources

Anti-HIV Cyclotides

Current Protein & Peptide Science, 2004
The cyclotides are a recently discovered, structurally unique family of bioactive plant peptides. Their discovery spawned a series of structural analyses, synthetic efforts, and studies to define the biosynthesis and biological properties of these novel peptide metabolites.
Kirk R, Gustafson   +2 more
openaire   +2 more sources

Emerging anti-HIV drugs

Expert Opinion on Emerging Drugs, 2005
There are now exactly 20 anti-HIV drugs licenced (approved) for clinical use, and > 30 anti-HIV compounds under (pre)clinical development. The licensed anti-HIV drugs fall into five categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy